Allele Frequency of CYP2C9 Gene Polymorphisms in Iran

F. Peyvandi; M. Spreafico; M. Karimi; S. Zeinali; P.M. Mannucci

doi:10.1055/s-0037-1613318

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 88(05): 874-875
DOI: 10.1055/s-0037-1613318

Letters to the Editor

Schattauer GmbH

Allele Frequency of CYP2C9 Gene Polymorphisms in Iran

Authors

F. Peyvandi

¹A. Bianchi Bonomi, Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital of Milan, Italy
M. Spreafico

¹A. Bianchi Bonomi, Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital of Milan, Italy
M. Karimi

²Nemazee Hospital, School of Medicine, Shiraz University of Medical Science, Iran
S. Zeinali

³Biotechnology Department Pasteur Institute of Teheran, Iran
P.M. Mannucci

¹A. Bianchi Bonomi, Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital of Milan, Italy

Abstract

Full Text

References

References
1 Miners J, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 535-8.
2 Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield CM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu³⁵⁹ allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 06: 341-9.
3 Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P4502C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
4 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
5 Garcìa-Martìn E, Martìnez C, Ladero JM, Gamito FJG, Agùndez JAG. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001; 57: 47-9.
6 Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Öngen Z, Nacak M, Roots I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-15.
7 Ackermann E, Cascorbi I, Sachse C, Brocmoller J, Mrozikiewiza PM, Roots I. Frequencies and the allelic linkage of CYP2C9 mutations in a German population and the detection of a C/T mutation in intron 2. Eur J Clin Pharmacol 1997; 52: A71
8 Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50.
9 Yasar Ü, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-31.
10 Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJJ, Stein CM, Wilkinson GR, Schwartz UI. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African-Americans. Mol Pharmacol 2001; 60: 382-7.